EUVIMEDAtrasti EUVIMED
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Multizentrische StudieOpen access · CC BY-NC-ND 4.0

Clinical Trial: Safety and Efficacy of a Novel Oesophageal Delivery System for Topical Corticosteroids Versus Placebo in the Treatment of Eosinophilic Oesophagitis

Alfredo J Lucendo iD, Óscar Nantes-Castillejo iD, Alex Straumann iD, Luc Biedermann iD, Albert J Bredenoord iD, Danila Guagnozzi iD, Leonardo Blas-Jhon iD, Anna Wiechowska-Kozlowska iD, Simon Weidlich iD, Ulrike von Arnim iD, Cecilio Santander-Vaquero, Antonia Perelló iD and 5 more

Alimentary Pharmacology & Therapeutics · 2025

DOI: 10.1111/apt.18443 ↗

At a glance

Randomisierte kontrollierte Studie in Alimentary Pharmacology & Therapeutics, 2025. Written by Alfredo J Lucendo and 16 co-authors. Institution: Department of Gastroenterology, Hospital General de Tomelloso, Tomelloso, Spain. Major MEDLINE topics: Adrenal Cortex Hormones, Drug Delivery Systems, Eosinophilic Esophagitis. Cited 5 times so far (Crossref); 41 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: EsoCap Biotech AG.

SantraukaSubjectsBibliografiniai duomenysCiteRelated studies

Abstract (original language)

Background

EsoCap is a thin mucoadhesive film designed to target the oesophageal mucosa. The device loaded with mometasone furoate (ESO‐101) is under investigation for the treatment of eosinophilic oesophagitis (EoE).

Aims

To evaluate the efficacy, safety and tolerability of ESO‐101 in patients with active EoE.

Methods

We conducted a randomised, placebo‐controlled, phase 2, proof‐of‐concept trial at 14 European sites in adults with EoE. Participants received placebo, uncoated EsoCap ( n = 15), or EsoCap loaded with 800 μg of mometasone furoate ( n = 28) once daily during 28 days. The primary outcome was the absolute change in the peak eosinophil count; secondary outcomes were histologic, clinical and endoscopic measures.

Results

Treatment with ESO‐101 resulted in reduction (mean ± SD) of 49.1 ± 88.4 eosinophils/high‐power field from baseline, compared with 6.6 ± 65.1 with placebo ( p = 0.03). With ESO‐101, 48% and 44% of patients achieved < 15 and < 6 eosinophils/high‐power field, respectively; these were 0% with placebo. EoE Endoscopic Reference Score reduced significantly in patients treated with ESO‐101. In contrast, dysphagia and odynophagia severity decreased similarly in both groups. There were no serious treatment‐emergent adverse events. Mean serum cortisol did not change significantly throughout the trial. Notably, no oropharyngeal or oesophageal candidiasis was documented. The device was well tolerated.

Conclusions

ESO‐101 was superior to placebo in reducing oesophageal eosinophilia. The device was safe and well tolerated in adults with EoE, supporting the continued development of ESO‐101 for the treatment of EoE ( Trials.gov No.: NCT04849390; Eu‐CT No.: 2020–000082‐16).

Subjects

MeSH terms (MEDLINE)

Adrenal Cortex HormonesDrug Delivery SystemsEosinophilic EsophagitisAdultAgedFemaleHumansMaleMiddle AgedYoung AdultAdministration, TopicalDouble-Blind MethodEsophagusMometasone FuroateTreatment OutcomePlacebos

Author keywords

corticosteroiddrug deliveryeosinophilic oesophagitishistopathologytopical therapy

Substances

Adrenal Cortex HormonesMometasone FuroatePlacebos

Authors and institutions

  • Department of Gastroenterology, Hospital General de Tomelloso, Tomelloso, Spain.
  • Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain.
  • Instituto de Investigación Sanitaria de Castilla-La Mancha (IDISCAM), Toledo, Spain.
  • Instituto de Investigación Sanitaria Princesa, Madrid, Spain.
  • Department of Gastroenterology, Complejo Hospitalario de Navarra, Pamplona, Spain.
  • IdiSNA. Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain.

ORCID profiles: Alfredo J Lucendo, Óscar Nantes-Castillejo, Alex Straumann, Luc Biedermann, Albert J Bredenoord, Danila Guagnozzi, Leonardo Blas-Jhon, Anna Wiechowska-Kozlowska, Simon Weidlich, Ulrike von Arnim, Antonia Perelló, Isabel Pérez-Martínez, Jesús Barrio, Michael Vieth, Ghazaleh Gouya, Evan S Dellon

Funding

  • EsoCap Biotech AG

Cite

APA

Lucendo, A. J., Nantes-Castillejo, Ó., Straumann, A., Biedermann, L., Bredenoord, A. J., Guagnozzi, D., Blas-Jhon, L., Wiechowska-Kozlowska, A., Weidlich, S., von Arnim, U., Santander-Vaquero, C., Perelló, A., Pérez-Martínez, I., Barrio, J., Vieth, M., Gouya, G., & Dellon, E. S. (2025). Clinical Trial: Safety and Efficacy of a Novel Oesophageal Delivery System for Topical Corticosteroids Versus Placebo in the Treatment of Eosinophilic Oesophagitis. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.18443

Vancouver

Lucendo AJ, Nantes-Castillejo Ó, Straumann A, Biedermann L, Bredenoord AJ, Guagnozzi D, et al. Clinical Trial: Safety and Efficacy of a Novel Oesophageal Delivery System for Topical Corticosteroids Versus Placebo in the Treatment of Eosinophilic Oesophagitis. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.18443

BibTeX
@article{Lucendo2025,
  author = {Lucendo, Alfredo J and Nantes-Castillejo, Óscar and Straumann, Alex and Biedermann, Luc and Bredenoord, Albert J and Guagnozzi, Danila and Blas-Jhon, Leonardo and Wiechowska-Kozlowska, Anna and Weidlich, Simon and von Arnim, Ulrike and Santander-Vaquero, Cecilio and Perelló, Antonia and Pérez-Martínez, Isabel and Barrio, Jesús and Vieth, Michael and Gouya, Ghazaleh and Dellon, Evan S},
  title = {Clinical Trial: Safety and Efficacy of a Novel Oesophageal Delivery System for Topical Corticosteroids Versus Placebo in the Treatment of Eosinophilic Oesophagitis},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2025},
  doi = {10.1111/apt.18443}
}
Start for free →